Abstract
The elimination of hepatitis C virus(HCV) infection is still a long way to go. Direct-acting antiviral agents (DAAs) can make HCV completely cured by targeting various stages of its replication life cycle and meanwhile standardize and simplify the treatment. However, those relative factors may affect efficacy and safety should be considered by specialties in choosing the suitable regimens. Therefore, this article reviews various aspects of DAAs including development history, factors correlated with efficacy and safety, therapeutic regimens domestic listed and approved.